Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Frequently asked questions
What sector does Omeros Corporation (OMER) operate in?
Omeros Corporation belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Omeros Corporation (OMER) current stock price?
As of the latest data, Omeros Corporation stock price is $16.29, with a previous close of $16.57. Omeros Corporation lost -$0.28 in the last trading session, representing a -1.69% loss.
What is Omeros Corporation (OMER) current market capitalization?
Omeros Corporation market cap is approximately 1.18 billion.
What is Omeros Corporation (OMER) Earnings Per Share (EPS)?
The trailing EPS is $1.65, and the forward EPS is $1.15.
What is Omeros Corporation (OMER) Price-to-Earnings (P/E) ratio?
Omeros Corporation current P/E ratio is 9.87, with a forward P/E of 14.23.
What is Omeros Corporation (OMER) EBITDA?
Omeros Corporation EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 17.58 million.
Does Omeros Corporation (OMER) pay dividends?
No. Omeros Corporation does not pay a dividend.
How did Omeros Corporation (OMER) perform in its most recent earnings report?
In the last report (June 30, 2026), Omeros Corporation posted an EPS surprise of 107.41% and a revenue surprise of 125.23%.
What is Omeros Corporation (OMER) beta (volatility) score?
Omeros Corporation has a beta of 2.603, indicating very high volatility compared to the market.
